{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-26-000056","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2026-08-11T11:32:26+00:00","discovered_at":"2026-08-11T11:35:00.262574+00:00","generated_at":"2026-08-11T11:35:21.376267+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurogene Q2 net loss $34.5M; NGN-401 100% milestone gains; cash to 1Q29","bullets":["Q2 2026 net loss $34.5M vs $22.0M YoY; R&D $25.5M, G&A $11.2M.","Cash $225.4M at June 30; pro forma $360.2M after $134.8M net from July offering; runway into 1Q29.","NGN-401 Phase 1/2: 100% (N=10) improved CGI-I and gained ≥1 milestone; avg 4.7 milestones, no plateau through 30 months.","Embolden topline data expected 2H 2027; PPQ runs for BLA complete by end-2026; NGN-401 well-tolerated (N=35).","Oversubscribed public offering raised ~$144M gross proceeds, including full underwriter option exercise."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-26-000056","json":"https://secwatch.observer/filing/0001404644-26-000056.json","markdown":"https://secwatch.observer/filing/0001404644-26-000056.md","text":"https://secwatch.observer/filing/0001404644-26-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/0001404644-26-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/ngne-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:35:21.376267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}